High expectations in pseudophakes fueling expansion in laser vision correction base

Article

Demand for excellent uncorrected distance visual acuity after cataract surgery is increasing, especially with the availability of new presbyopia-correcting IOLs. This phenomenon is opening up a new class of patients to the benefits of laser vision correction.

Demand for excellent uncorrected distance visual acuity after cataract surgery is increasing, especially with the availability of new presbyopia-correcting IOLs. This phenomenon is opening up a new class of patients to the benefits of laser vision correction, said Steven J. Dell, MD, at Refractive Surgery Subspecialty Day.

"If cataract surgery is now being considered refractive surgery, then cataract surgery with implantation of a premium IOL is hyper-refractive surgery," said Dr. Dell, director, refractive and corneal surgery, Texan Eye, Austin, TX. "Recipients of these lenses are less tolerant of misses in our refractive target than their younger, laser vision correction counterparts. This is because a low hyperopic result in a young phakic patient may still result in 20/15 vision, but is totally unacceptable in a pseudophake.

"If refractive errors occur in sphere and/or cylinder, there are a number of options for correcting them. However, laser vision correction is the most accurate," Dr. Dell said.

When a decision is made to proceed with a laser vision enhancement, surgeons need to consider whether to perform a customized ablation or a conventional procedure.

Dr. Dell suggested performing a wavefront-guided procedure in the eyes of patients who have received either a monofocal lens, accommodating lens (crystalens, eyeonics), apodized diffractive lens (AcrySof ReSTOR, Alcon Laboratories), or multifocal lens (Tecnis, Advanced Medical Optics), assuming the wavefront is capturable and the data make sense. However, he cautioned against a custom wavefront-guided enhancement in eyes in which the zonal refractive multifocal IOL (ReZoom, Advanced Medical Optics) is implanted.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.